查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1386389

次单位疫苗市场报告：2030 年趋势、预测与竞争分析

Subunit Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

次单位疫苗趋势和预测

至2030年，全球次单位疫苗市场预计将达到24亿美元，2024年至2030年的复合年增长率为10.5%。该市场的主要驱动因素是免疫接种和高安全性疫苗需求的增加以及感染疾病流行的增加。全球次单位疫苗市场前景看好，感染疾病、白喉、破伤风、百日咳（DTP）、HPV、麻疹、腮腺炎和德国德国麻疹（MMR）市场充满机会。

次单位疫苗市场洞察

Lucintel 预测，由于蛋白质抗原亚次单位疫苗的广泛可用性和易于采用，蛋白质将继续占据很大一部分。

由于感染疾病高发，北美仍然是最大的地区。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去五年发生了哪些併购事件，对产业产生了哪些影响？

目录

第一章执行摘要

第二章全球次单位疫苗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球次单位疫苗市场趋势（2018-2023）与预测（2024-2030）
  • 按产品类型分類的全球次单位疫苗市场
    • 蛋白质抗原
    • 多醣体抗原
  • 按疾病分類的全球次单位疫苗市场
    • 感染疾病
    • 白喉
    • 破伤风和百日咳 (DTP)
    • HPV
    • 麻疹
    • 流行性腮腺炎和德国麻疹(MMR)
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球次单位疫苗市场（按地区）
  • 北美亚次单位疫苗市场
  • 欧洲次单位疫苗市场
  • 亚太亚次单位疫苗市场
  • 其他区域次单位疫苗市场

第五章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 按产品类型分類的全球次单位疫苗市场成长机会
    • 全球次单位疫苗市场按疾病分類的成长机会
    • 全球次单位疫苗市场成长机会（按地区）
  • 全球次单位疫苗市场的新趋势
  • 战略分析
    • 新产品开发
    • 全球次单位疫苗市场产能扩张
    • 全球次单位疫苗市场的合併、收购和合资企业
    • 认证和许可

第七章主要企业概况

  • GE Healthcare Life Sciences
  • GlaxoSmithKline
  • Merck
  • Reber Genetics
  • Sanofi
  • Algenex
  • Astellas Pharma
简介目录

Subunit Vaccine Trends and Forecast

The future of the global subunit vaccine market looks promising with opportunities in the infectious disease, diphtheria, tetanus and pertussis (DTP), HPV, measles, and mumps & rubella (MMR) markets. The global subunit vaccine market is expected to reach an estimated $2.4 billion by 2030 with a CAGR of 10.5% from 2024 to 2030. The major drivers for this market are rising demand for immunization and better safety vaccines and growing prevalence of infectious diseases.

A more than 150-page report is developed to help in your business decisions.

Subunit Vaccine by Segment

The study includes a forecast for the global subunit vaccine by product type, disease, and region.

Subunit Vaccine Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:

  • Protein Antigen
  • Polysaccharide Antigen

Subunit Vaccine Market by Disease [Shipment Analysis by Value from 2018 to 2030]:

  • Infectious Disease
  • Diphtheria
  • Tetanus and Pertussis (DTP)
  • HPV
  • Measles
  • Mumps and Rubella (MMR)
  • Others

Subunit Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Subunit Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies subunit vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the subunit vaccine companies profiled in this report include-

  • GE Healthcare Life Sciences
  • GlaxoSmithKline
  • Merck
  • Reber Genetics
  • Sanofi
  • Algenex
  • Astellas Pharma

Subunit Vaccine Market Insights

Lucintel forecasts that protein will remain the larger segment due to its widespread availability and adoptability of protein antigen subunit vaccines.

North America will remain the largest region due to the high prevalence of infectious diseases in this region.

Features of the Global Subunit Vaccine Market

Market Size Estimates: Subunit vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Subunit vaccine market size by product type, disease, and region in terms of value ($B).

Regional Analysis: Subunit vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, diseases, and regions for the subunit vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the subunit vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the subunit vaccine market size?

Answer: The global subunit vaccine market is expected to reach an estimated $2.4 billion by 2030.

Q.2 What is the growth forecast for subunit vaccine market?

Answer: The global subunit vaccine market is expected to grow with a CAGR of 10.5% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the subunit vaccine market?

Answer: The major drivers for this market are rising demand for immunization and better safety vaccines and growing prevalence of infectious diseases.

Q4. What are the major segments for subunit vaccine market?

Answer: The future of the subunit vaccine market looks promising with opportunities in the infectious disease, diphtheria, tetanus and pertussis (DTP), HPV, measles, and mumps & rubella (MMR) markets.

Q5. Who are the key subunit vaccine market companies?

Answer: Some of the key subunit vaccine companies are as follows:

  • GE Healthcare Life Sciences
  • GlaxoSmithKline
  • Merck
  • Reber Genetics
  • Sanofi
  • Algenex
  • Astellas Pharma

Q6. Which subunit vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that protein will remain the larger segment due to its widespread availability and adoptability of protein antigen subunit vaccines.

Q7. In subunit vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region due to the high prevalence of infectious diseases in this region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the subunit vaccine market by product type (protein antigen and polysaccharide antigen), disease (infectious disease, diphtheria, tetanus and pertussis (DTP), HPV, measles, mumps and rubella (MMR), and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Subunit Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Subunit Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Subunit Vaccine Market by Product Type
    • 3.3.1: Protein Antigen
    • 3.3.2: Polysaccharide Antigen
  • 3.4: Global Subunit Vaccine Market by Disease
    • 3.4.1: Infectious Disease
    • 3.4.2: Diphtheria
    • 3.4.3: Tetanus and Pertussis (DTP)
    • 3.4.4: HPV
    • 3.4.5: Measles
    • 3.4.6: Mumps and Rubella (MMR)
    • 3.4.7: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Subunit Vaccine Market by Region
  • 4.2: North American Subunit Vaccine Market
    • 4.2.2: North American Subunit Vaccine Market by Disease: Infectious Disease, Diphtheria, Tetanus and Pertussis (DTP), HPV, Measles, Mumps and Rubella (MMR), and Others
  • 4.3: European Subunit Vaccine Market
    • 4.3.1: European Subunit Vaccine Market by Product Type: Protein Antigen and Polysaccharide Antigen
    • 4.3.2: European Subunit Vaccine Market by Disease: Infectious Disease, Diphtheria, Tetanus and Pertussis (DTP), HPV, Measles, Mumps and Rubella (MMR), and Others
  • 4.4: APAC Subunit Vaccine Market
    • 4.4.1: APAC Subunit Vaccine Market by Product Type: Protein Antigen and Polysaccharide Antigen
    • 4.4.2: APAC Subunit Vaccine Market by Disease: Infectious Disease, Diphtheria, Tetanus and Pertussis (DTP), HPV, Measles, Mumps and Rubella (MMR), and Others
  • 4.5: ROW Subunit Vaccine Market
    • 4.5.1: ROW Subunit Vaccine Market by Product Type: Protein Antigen and Polysaccharide Antigen
    • 4.5.2: ROW Subunit Vaccine Market by Disease: Infectious Disease, Diphtheria, Tetanus and Pertussis (DTP), HPV, Measles, Mumps and Rubella (MMR), and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Subunit Vaccine Market by Product Type
    • 6.1.2: Growth Opportunities for the Global Subunit Vaccine Market by Disease
    • 6.1.3: Growth Opportunities for the Global Subunit Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Subunit Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Subunit Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Subunit Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: GE Healthcare Life Sciences
  • 7.2: GlaxoSmithKline
  • 7.3: Merck
  • 7.4: Reber Genetics
  • 7.5: Sanofi
  • 7.6: Algenex
  • 7.7: Astellas Pharma